Incorporating future medical costs: impact on cost-effectiveness analysis in cancer patients

PharmacoEconomics

12 June 2019 - The inclusion of future medical costs in cost-effectiveness analyses remains a controversial issue. 

The impact of capturing future medical costs is likely to be particularly important in patients with cancer where costly lifelong medical care is necessary. The lack of clear, definitive pharmacoeconomic guidelines can limit comparability and has implications for decision making.

The aim of this study was to demonstrate the impact of incorporating future medical costs through an applied example using original data from a clinical study evaluating the cost effectiveness of a sepsis intervention in cancer patients.

Read PharmacoEconomics article

Michael Wonder

Posted by:

Michael Wonder